Genomics pioneer steps closer to dementia treatment breakthrough
An Icelandic scaleup has sparked hopes of a breakthrough in dementia treatment after raising €26.5mn for groundbreaking research. Arctic Therapeutics (ATx) attracted the investment after pioneering a new approach to drug development. Founded in 2015, the company first analyses genomic data with bioinformatics — a blend of computer science and biology. After identifying disease-associated genes and proteins, ATx targets the root causes of a given condition. According to the scaleup, the process cuts the risks, costs, and time involved in developing treatments. The new financing could push the benefits closer towards patients. ATx said the Series A funds will advance…This story continues at The Next Web
An Icelandic scaleup has sparked hopes of a breakthrough in dementia treatment after raising €26.5mn for groundbreaking research. Arctic Therapeutics (ATx) attracted the investment after pioneering a new approach to drug development. Founded in 2015, the company first analyses genomic data with bioinformatics — a blend of computer science and biology. After identifying disease-associated genes and proteins, ATx targets the root causes of a given condition. According to the scaleup, the process cuts the risks, costs, and time involved in developing treatments. The new financing could push the benefits closer towards patients. ATx said the Series A funds will advance…
This story continues at The Next Web
What's Your Reaction?
